Annexon’s Board of Directors is comprised of accomplished leaders in global biotechnology and the pharmaceutical industry, with expertise in governance, research, development and commercialization. Our Board plays a central role in guiding the company toward rapid advancement of our novel product pipeline. 

William (Bill) Young, Board Chair

Industry executive & Board member

Mr. Young joined Clarus Ventures in 2010 as a Venture Partner from Monogram Biosciences, a leader in personalized medicine, where he served as chief executive officer from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young currently serves on the Board of Directors of BioMarin (NASDAQ:BMRN), Theravance (NASDAQ:TBPH), and Vertex (NASDAQ: VRTX) and Annexon Biosciences. Previously he was Chairman of the Board of Biogen IDEC (NASDAQ: BIIB). Prior to Monogram he was at Genentech since 1980 at positions of increasing responsibility, including chief operating officer responsible for all of the biotechnology company’s development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years.

Mr. Young received his bachelor’s degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.

Doug Love, Esq, Board Member


Mr. Love joined Annexon Biosciences as Chief Executive Officer in April 2014 with extensive business and legal leadership experience in biotech. He previously served as Head of Operations for Elan Pharmaceuticals. There, Mr. Love led the Tysabri® multiple sclerosis franchise, helping to propel it to nearly $2 billion in annual sales.  He also led Elan’s Alzheimer’s Immunotherapy Program, which was licensed to Johnson & Johnson for $1 billion plus milestones and royalties, as well as Elan’s global Commercial, Medical Affairs ad Alliance Management groups. Mr. Love is a corporate attorney by training, and prior to joining Elan served as an associate at the law firm Orrick, Herrington & Sutcliffe, Corporate Counsel at Amgen, Inc. and as Section Corporate Counsel at Genentech Inc., where he led the BioOncology Healthcare Law Group and launched several blockbuster programs. Mr. Love holds a J.D. with great distinction from McGeorge School of Law, Sacramento, CA, and a B.S. in business administration from the University of Southern California.

Campbell Murray, MD, Board Member


Dr. Campbell Murray is a Managing Director at Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he worked at the Novartis Institutes for BioMedical Research as the Director of Special Projects. Campbell is a New Zealand-trained physician and worked as a Medical House Officer at Auckland Hospital. He is a Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government, where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell serves on the boards of Aerpio, Annexon, BioNano Genomics, Galera, ImaginAb and Neurovance.

Muneer Satter, Board Member


Muneer A. Satter manages Satter Investment Management (SIM), a private investment firm and family office. He also manages the Satter Foundation, a private family foundation. SIM has significant investments in several life sciences and medical technology companies.

Mr. Satter is co-chairman and lead director of Vital Therapies, a publicly traded biotech company that has created an artificial liver for patients suffering from acute liver failure. He is chairman of Akebia Therapeutics, a publicly traded biotech company focused on the treatment of anemia. He is co-chairman of Aerpio Therapeutics, a biotech company with a TIE-2 activator for diabetic macular edema and vascular leaks. He is a director of Annexon which is a complement cascade pathway company focused on autoimmune and neurologic diseases. He is chairman and co-founder of Restorsea, a company which holds exclusive rights to a unique enzyme for an anti-aging cream. He is chairman of Linq3, a unique secure payment platform for lottery transactions.

He is vice chairman of the Board of the Goldman Sachs Foundation and GS Gives, where he is also chairman of the Investment Committee overseeing $1.2 billion of assets. He is a member of the Board of Northwestern University where he is chairman of the Finance Committee. He is also a member of the Board of the Navy SEAL Foundation. He is a member of the advisory board of NatureVest, the impact investment unit of the Nature Conservancy. Additionally, he is on the Board of Advisors of the American Enterprise Institute and the Board of World Business Chicago (chaired by Mayor Rahm Emanuel). He is a member of the Council on Foreign Relations. He is a former co-chairman of Room to Read (which builds 2,000 libraries and schools per year in developing countries). He is a former member of the Board of the Nature Conservancy where he was chairman of the Finance Committee overseeing a $1.8 billion endowment.

Mr. Satter is a retired partner at Goldman Sachs, where he was a partner of the firm for 16 years. He spent his career in the Merchant Banking Division which manages the firm’s private investments. Mr. Satter joined Goldman Sachs in 1988 and moved to London in 1992 to start up and co-head the firm’s Merchant Banking Group in Europe. He later returned to New York and was the global head of the Mezzanine Group, where he raised and managed over $30 billion of assets. He was also a senior member of the Investment Committee and chairman of the Risk Committee for the Merchant Banking Division, which at the time had more than $80 billion of assets under management.

Mr. Satter received a B.A. from Northwestern University, and a JD/MBA from Harvard Law School and Harvard Business School. He lives in Chicago, IL with his wife, Kristen, and their five daughters.

Emmett Cunningham, MD, PhD, MPH, Board Member


Dr. Cunningham joined Clarus Ventures ( in 2006 with more than 20 years experience in the biomedical and biopharmaceutical sectors. He is currently a Partner at Clarus. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.

Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications. He is Director of the Uveitis Service at California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University, and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. Dr. Cunningham was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology with Prof. Alfred Sommer at the Wilmer Eye Institute in Baltimore.

Dr. Cunningham is a member of the Board of Directors of Restoration Robotics, Annexon Biosciences, and SFJ V, and on the Scientific Advisory Board of Aerie Pharmaceuticals, Inc. (Nasdaq: AERI). He was until recently on the Boards of Neomend, Inc. (acquired by CR Bard, Inc., NYSE: BCR) and SARcode BioSceinces (acquired by Shire, plc, Nasdaq: SHPG). Dr. Cunningham is a Board observer for Avillion, and was until recently a Board observer for Aerie (Nasdaq: AERI), Ophthotech Corporation (Nasdaq: OPHT), Pearl Therapeutics (acquired by AstraZeneca, plc, NYSE: AZN), Ferrokin (acquired by Shire).

Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, a well-attended symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. The OIS brings together leading companies, clinicians, academics and investors in the ophthalmology space.

Frank Torti, MD, Board Member

Partner, New Enterprise Associates, Inc.

Frank Torti joined NEA in 2007 and focuses on investments in biopharmaceuticals, medical devices, and healthcare services. He has been actively involved in the firm’s private and public investments in healthcare, including Annexon Biosciences, Alimera Sciences, Cadence Pharmaceuticals (acquired by Mallinckrodt plc), Cerecor, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceuticals), Dermira, GST Clinics, Galera Therapeutics, Neotract, Novast Pharmaceuticals, Peplin (acquired by LEO Pharma), Rigel, Solta Medical (acquired by Valeant), and Tarveda Therapeutics.

Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti's experience also includes public market investing at the Wasatch Advisors mutual fund family and business development work with the consumer-directed healthcare startup Revolution Health Group. He received his medical degree from the University of North Carolina School of Medicine, his MBA with distinction from Harvard Business School, and his BA with highest honors from the University of North Carolina, where he was a Morehead Scholar.

Thomas G. Wiggans, Independent Board Member

Founder & CEO, Dermira

Tom Wiggans co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. He brings over 30 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, he served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006.  Prior to Connetics, he served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. He began his career with Eli Lilly and Company.

Mr. Wiggans has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc.

In addition, Mr. Wiggans is a member of the board of directors of Biotechnology Innovation Organization, a non-profit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. He holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.

Arnon Rosenthal, PhD, Co-founder, Board Observer

Co-Founder & CEO, Alector

Arnon Rosenthal received his PhD from the Hebrew University Jerusalem, Israel, and then conducted a postdoctoral fellowship at Genentech, Inc. Following his postdoc, he was appointed to a scientist position at Genentech Inc., and was later promoted to a senior scientist and then to staff scientist and permanent member of Genentech Research Review Committee.

Dr. Rosenthal is co-founder of Rinat Neuroscience, a privately-held company that discovered and developed novel medicines for neurodegenerative, neuroendocrine and pain disorders, where he also served as President, board member and CSO. Rinat was acquired by Pfizer with several drugs in clinical development, including Tanezumab which is currently in Phase 3 for multiple pain indications, PF-04360365 which entered Phase 2 for Alzheimer’s disease and RN-307 which entered the clinic for migraine.

Dr. Rosenthal is also co-founder and board chair of Annexon Biosciences and co-founder, President and CEO of Alector LLC, a privately held biotechnology company focused on the discovery and development of novel therapies for Alzheimer’s disease and other forms of dementia. Dr. Rosenthal is a visiting professor of the Department of Anatomy at the University of California San Francisco and a member of the scientific advisory boards of Simons Foundation, Autism Research Initiative and the Myelin Repair Foundation. He has co-authored 108 scientific publications and over 380 issued patents and applications.

Giovanni Ferrara, Board Observer

Venture Partner, Novartis Venture Fund

Giovanni Ferrara is a Venture Partner at Novartis Venture Fund in Cambridge, MA, USA. Prior to joining NVF, he was a consultant to leading west coast venture capital firms and portfolio companies. Most recently, Giovanni was consulting Chief Business Officer to Sorbent Therapeutics. Previously, he was Managing Director and General Partner at Burrill & Company and began his venture capital career at GeneChem Management, where in addition to investing, he held operating positions in portfolio companies, including CEO of Targanta Therapeutics (then PhageTech, Inc.). He began his career in healthcare as a pharmacist at a cancer treatment center researching experimental therapies. He received his MBA and MSc from McGill University. Giovanni serves on the board of Thesan Pharmaceuticals.